Equities analysts expect that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post earnings of $0.07 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.02 and the highest estimate coming in at $0.12. Vanda Pharmaceuticals reported earnings of $0.20 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 65%. The firm is expected to report its next earnings results on Wednesday, November 6th.
On average, analysts expect that Vanda Pharmaceuticals will report full year earnings of $0.30 per share for the current fiscal year, with EPS estimates ranging from $0.27 to $0.33. For the next financial year, analysts expect that the company will post earnings of $0.98 per share, with EPS estimates ranging from $0.20 to $1.75. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.24. The firm had revenue of $59.06 million during the quarter, compared to analysts’ expectations of $54.19 million. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.15 earnings per share.
In other news, Director Richard W. Dugan sold 15,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.85, for a total value of $222,750.00. Following the sale, the director now owns 50,770 shares of the company’s stock, valued at $753,934.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Timothy Williams sold 2,575 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $14.69, for a total transaction of $37,826.75. Following the completion of the sale, the senior vice president now directly owns 57,425 shares in the company, valued at approximately $843,573.25. The disclosure for this sale can be found here. Insiders own 8.20% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio raised its position in Vanda Pharmaceuticals by 19.5% during the second quarter. Strs Ohio now owns 50,800 shares of the biopharmaceutical company’s stock worth $715,000 after acquiring an additional 8,300 shares in the last quarter. Stonepine Capital Management LLC raised its position in Vanda Pharmaceuticals by 6.5% during the second quarter. Stonepine Capital Management LLC now owns 1,341,943 shares of the biopharmaceutical company’s stock worth $18,908,000 after acquiring an additional 81,655 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Vanda Pharmaceuticals by 4.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 454,759 shares of the biopharmaceutical company’s stock worth $6,408,000 after acquiring an additional 18,447 shares in the last quarter. Northern Trust Corp raised its position in Vanda Pharmaceuticals by 1.0% during the second quarter. Northern Trust Corp now owns 706,666 shares of the biopharmaceutical company’s stock worth $9,957,000 after acquiring an additional 6,938 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in Vanda Pharmaceuticals during the second quarter worth $272,000.
NASDAQ VNDA traded down $0.03 during trading on Friday, reaching $13.66. 334,000 shares of the stock traded hands, compared to its average volume of 772,878. The firm has a market cap of $726.66 million, a price-to-earnings ratio of 28.46 and a beta of 0.32. The stock’s 50-day moving average price is $13.43 and its 200 day moving average price is $14.68. Vanda Pharmaceuticals has a fifty-two week low of $11.83 and a fifty-two week high of $33.44.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Read More: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.